197 related articles for article (PubMed ID: 35803902)
21. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
Knecht KM; Buzovetsky O; Schneider C; Thomas D; Srikanth V; Kaderali L; Tofoleanu F; Reiss K; Ferreirós N; Geisslinger G; Batista VS; Ji X; Cinatl J; Keppler OT; Xiong Y
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10022-E10031. PubMed ID: 30305425
[TBL] [Abstract][Full Text] [Related]
22. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
[TBL] [Abstract][Full Text] [Related]
23. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
24. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
25. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
[TBL] [Abstract][Full Text] [Related]
26. The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.
Yang J; Li L; Cheng J; Lu J; Zhang S; Wang S; Zhao L; Zhou L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11457-11469. PubMed ID: 37391640
[TBL] [Abstract][Full Text] [Related]
27. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
28. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia.
Wang Y; Wang D; Wang Y; Yang H; Wang G; Wu S
Neoplasma; 2023 Apr; 70(2):287-293. PubMed ID: 36812234
[TBL] [Abstract][Full Text] [Related]
30. MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.
Hu N; Chen L; Wang C; Zhao H
Biomed Pharmacother; 2019 Apr; 112():108720. PubMed ID: 30970520
[TBL] [Abstract][Full Text] [Related]
31. Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Chiou JT; Hsu CC; Hong YC; Lee YC; Chang LS
Biochem Pharmacol; 2023 May; 211():115494. PubMed ID: 36924905
[TBL] [Abstract][Full Text] [Related]
32. SAMHD1 is a barrier to antimetabolite-based cancer therapies.
Rudd SG; Schaller T; Herold N
Mol Cell Oncol; 2017; 4(2):e1287554. PubMed ID: 28401188
[TBL] [Abstract][Full Text] [Related]
33. Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma.
Merrien M; Wasik AM; Ljung E; Morsy MHA; de Matos Rodrigues J; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
Virchows Arch; 2022 Mar; 480(3):655-666. PubMed ID: 34738194
[TBL] [Abstract][Full Text] [Related]
34. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
35. TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis.
Zhang B; Sun YF; Zhang XM; Jiang N; Chen Q
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4940-4953. PubMed ID: 32432757
[TBL] [Abstract][Full Text] [Related]
36. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
37. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
39. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
[TBL] [Abstract][Full Text] [Related]
40. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
